Has Jasmin Jo, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,020 in general payments to Jasmin Jo, MD across 47 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jasmin Jo, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jasmin Jo, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jasmin Jo, MD

Neurology · Charlottesville, VANPI 1831487172

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $805 of the $1,020 with a category attached, or 78.9%. 23 manufacturers reported payments, led by Incyte Corporation at 24.2% of the total. Reporting peaked in 2019 at $409 and has fallen 56.2% since, to $179 in 2025. That places this record below the midpoint for neurology clinicians in VA, where the typical reported total is $1,288.

$1,020in general payments, 2019–2025

Across 47 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Incyte Corporation$247
Novocure Inc.$128
Pfizer$68
Merck$59
Amgen$48
Genentech USA, Inc.$48
plus $423 from 17 others

$583in research payments, 2019–2025

Across 22 payments — averaging $26.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Incyte Corporation$583

What the payments were for

Food & beverage$80579%
Education$21521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Incyte Corporation	6	$247
Novocure Inc.	1	$128
Pfizer	4	$68
Merck	3	$59
Amgen	3	$48
Genentech USA, Inc.	4	$48
Tesaro, Inc.	2	$45
Cala Health, Inc.	1	$43
E.r. Squibb & Sons, L.L.C.	2	$37
Takeda Pharmaceuticals U.S.A., Inc.	3	$36
Lilly USA, LLC	2	$33
Jazz Pharmaceuticals Inc.	2	$31
GSK	2	$30
AstraZeneca(2 entities)	2	$27
Sanofi	2	$24
Daiichi Sankyo Inc.	1	$19
Bristol Myers Squibb	1	$19
Astellas Pharma US Inc	1	$16
AMAG Pharmaceuticals, Inc.	1	$15
Seagen Inc.	1	$14
Shire North American Group Inc	1	$13
Kyowa Kirin, Inc.	1	$12
Secura Bio, Inc.	1	$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Optune Gio$128

How this compares

$1,020 in reported general payments places this provider in the 45th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia →

Medicare billing

Part B allowed, 2024

$41,229

Medicare patients

Services billed

422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
FycompaPerampanel	11	$9,299
Lacosamide	46	$6,425
Levetiracetam	142	$2,928
Levetiracetam ErLevetiracetam	15	$2,250
Dexamethasone	42	$654
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine	15	$546
Ondansetron Hcl	17	$546
Lamotrigine	18	$342
Zonisamide	20	$334
Gabapentin	40	$328
Topiramate	29	$238
Mirtazapine	11	$72
Clonazepam	11	$33
Tamsulosin Hcl	11	$33
Fluoxetine Hcl	19	$32

Paid to pharmacies, not to this prescriber.

Other neurology in Charlottesville

Robert ShinCharlottesville$1.7M
Brian WeinshenkerCharlottesville$195K
Robert SawyerCharlottesville$55K
Nathan FountainCharlottesville$45K
Helen Dainton-HowardCharlottesville$41K
Alissa HiginbothamCharlottesville$37K
Ramsey FalconerAlexandria$2M
Heidi CraytonVienna$1.5M
Mark LandrioWinchester$631K
Catherine HamRichmond$603K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →